Abstract: The present invention relates to an oral pharmaceutical composition of aliphatic amine polymer or salts thereof comprising mixture of water and organic solvent(s) and/or less than of about 10% of plasticizing agent in the coating composition. In particular, present invention relates to a coated pharmaceutical composition of aliphatic amine polymer or salt thereof which comprises mixture of water and organic solvent(s) and less than of about 10% of plasticizing agent in coating. The invention also includes process of preparing such composition.
Type:
Grant
Filed:
February 5, 2014
Date of Patent:
February 14, 2017
Assignee:
WOCKHARDT LIMITED
Inventors:
Girish Kumar Jain, Venkataramana Naidu, Abdul Rehman Khan, Amar Agarwal, Srikanth Pattipati
Abstract: A process for preparation of a sodium salt of (2S,5R)-2-carboxamido-7-oxo-6-sulfooxy-1,6-diaza-bicyclo[3.2.1]octane is disclosed which is comprising the amidation of a compound of Formula (II) to obtain a compound of Formula (III).
Abstract: Pharmaceutical compositions comprising aztreonam or a pharmaceutically acceptable derivative, and a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof are disclosed.
Abstract: Pharmaceutical compositions comprising ceftolozane or a pharmaceutically acceptable derivative, and a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof are disclosed.
Abstract: A process for preparation of (2S, 5R)-Sulfuric acid mono-{[(4-aminopiperidin-4-yl) carbonyl]-7-oxo-1,6-diaza-bicyclo[3.2.1]-oct-6-yl} ester is disclosed which comprises reacting a compound of Formula (II) with a compound of Formula (III) to obtain a compound of Formula (IV).
Abstract: Pharmaceutical compositions comprising sulbactam or a pharmaceutically acceptable derivative thereof, and compound of Formula (I) or a stereoisomer or a pharmaceutical acceptable derivative thereof, are disclosed.
Abstract: There is provided a once-a-day therapeutically synergistic pharmaceutical dosage form for treatment of cardiovascular disorders, wherein the dosage form comprises a fixed dose combination of metoprolol in extended release form and one or more calcium channel blocker, angiotensin II receptor blocker or angiotensin converting enzyme inhibitor along with one or more rate controlling excipient.
Abstract: This invention relates to a compliance blister package comprising a matrix of blisters arranged in a plurality of columns and plurality of rows which comprises a combination of one of the fixed dose combination dosage form comprising two or more therapeutically active ingredients loaded into blisters of one of the columns and the other dosage form which comprises one or more of therapeutically active ingredient form loaded into the successive column blisters for once a day administration or concurrent administration.
Abstract: The present invention relates to novel tablet dosage forms and methods of preparing these forms, which can be used for different classes of pharmaceutical active ingredients posing stability issues in a single unit system. The dosage form includes a first layer, which includes a tablet of one or more active pharmaceutical ingredients, which is inlayed in the first layer along with other pharmaceutically acceptable excipients, and a second layer that includes one or more active pharmaceutical ingredients optionally with other pharmaceutically acceptable excipients.
Abstract: The present invention refers to a modified release pharmaceutical composition comprising desvenlafaxine or salts thereof, a release rate modifying system that controls the release of active agent(s) in both acidic and basic environments. A process of making and method of using the above-described composition is also disclosed.
Abstract: The present invention relates to stable pharmaceutical compositions comprising entacapone, levodopa and carbidopa, or pharmaceutically acceptable salts or hydrates thereof. The invention also relates to processes for the preparation of such compositions.
Abstract: The present invention relates to improved child resistant carton and methods for using the same. The improved child resistant carton comprises housing (1) and an insert (4). The housing comprises a locking mechanism (3). The housing (1) may be made from multiple panels. The panel may be of any shape and may be more than one. The housing (1) may be made of card board. The locking mechanism (3) is characterized in that the locking and releasing of the carton has improved child resistance characteristics.
Abstract: The present invention relates to pharmaceutical compositions of duloxetine or pharmaceutically acceptable salts thereof, and processes for their preparation.